이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

신생혈관 연령 관련 황반 변성에서 Beovu를 투여받은 환자의 체액 분해능 및 효과를 평가하기 위한 관찰 연구 (BLUE SKY)

2026년 11월 17일 업데이트: Novartis Pharmaceuticals

신생혈관 연령 관련 황반 변성에서 주요 치료 계획 하에서 Beovu(Brolucizumab)를 투여받은 환자의 체액 분해능 및 효과를 평가하기 위한 관찰 연구

This study was a prospective, non-interventional, multicenter, open-label study in nAMD and DME patients being treated with brolucizumab according to the EU SmPC.

An observational study design, without a strict, mandated visit schedule or mandated treatment regimen was chosen as the most appropriate to collect available data in a real life setting. For that reason, this NIS did not impose a therapy protocol, diagnostic/therapeutic procedure or a visit schedule. The diagnostic or monitoring procedures were only those ordinarily applied to the therapeutic strategy and to routine clinical care and took place as per investigator's discretion. This included e.g. visit frequency, injection frequency and types of assessments performed - only data from routine medical practice was collected as part of the study.

연구 개요

상세 설명

BLUE SKY consisted of the nAMD-related module BIRL (Brolucizumab In Real Life) and two general, indication-related study modules "BLUE SKY AMD" and "BLUE SKY DME".

Patients were enrolled at 40 centers, which were representatively distributed amongst the 16 German federal states. This should reflect all state-specific health insurance laws and guidelines. Naïve and pre-treated patients were included after decision to start treatment with brolucizumab and consent was given.

All patients were documented either in the AMD or DME-module (Full Analysis Set).

For the BIRL module, only naïve nAMD patients enrolled in 7 selected centers were planned to be documented. All these centers were equipped with the Zeiss PlexElite OCT-A, needed to assess and analyze BIRL specific objectives in a comparable setting. Only images from routine medical practice were collected as part of the study. The study eye was defined as the first eye treated during the study, the other eye was considered as fellow eye. If both eyes were treated at baseline, the eye with the worse VA was chosen as the study eye (if VA was measured equal, the treating ophthalmologist defines the study eye upon his discretion). The prospective observation period per patient was up to 24 months.

연구 유형

관찰

등록 (실제)

572

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 장소

      • Aschersleben, 독일, 06449
        • Novartis Investigative Site
      • Bayreuth, 독일, 95445
        • Novartis Investigative Site
      • Berlin, 독일, 10713
        • Novartis Investigative Site
      • Berlin, 독일, 14163
        • Novartis Investigative Site
      • Bonn, 독일, 53105
        • Novartis Investigative Site
      • Breisach, 독일, 79206
        • Novartis Investigative Site
      • Chemnitz, 독일, 09113
        • Novartis Investigative Site
      • Cologne, 독일, 50968
        • Novartis Investigative Site
      • Dresden, 독일, 01067
        • Novartis Investigative Site
      • Dresden, 독일, 01324
        • Novartis Investigative Site
      • Esslingen am Neckar, 독일, 73728
        • Novartis Investigative Site
      • Glauchau, 독일, 08371
        • Novartis Investigative Site
      • Homburg, 독일, 66421
        • Novartis Investigative Site
      • Hösbach, 독일, 63768
        • Novartis Investigative Site
      • Kiel, 독일, 24103
        • Novartis Investigative Site
      • Leipzig, 독일, 04106
        • Novartis Investigative Site
      • Magdeburg, 독일, 39104
        • Novartis Investigative Site
      • Marienberg, 독일, 09496
        • Novartis Investigative Site
      • Münster, 독일, 48145
        • Novartis Investigative Site
      • Neubrandenburg, 독일, 17036
        • Novartis Investigative Site
      • Schönebeck, 독일, 39218
        • Novartis Investigative Site
      • Stralsund, 독일, 18435
        • Novartis Investigative Site
      • Sulzbach, 독일, 66280
        • Novartis Investigative Site
      • Torgau, 독일, 04860
        • Novartis Investigative Site
      • Waren, 독일, 17192
        • Novartis Investigative Site
      • Würzburg, 독일, 97080
        • Novartis Investigative Site
    • Bavaria
      • Munich, Bavaria, 독일, 81377
        • Novartis Investigative Site
      • Neuburg A.d. Donau, Bavaria, 독일, 86633
        • Novartis Investigative Site
      • Würzburg, Bavaria, 독일, 97080
        • Novartis Investigative Site
      • Würzburg, Bavaria, 독일, 97070
        • Novartis Investigative Site
    • Hesse
      • Frankfurt am Main, Hesse, 독일, 60590
        • Novartis Investigative Site
    • Lower Saxony
      • Göttingen, Lower Saxony, 독일, 37075
        • Novartis Investigative Site
      • Osnabrück, Lower Saxony, 독일, 49076
        • Novartis Investigative Site
    • Mecklenburg-Vorpommern
      • Rostock, Mecklenburg-Vorpommern, 독일, 18057
        • Novartis Investigative Site
    • Rhineland-Palatinate
      • Trier, Rhineland-Palatinate, 독일, 54296
        • Novartis Investigative Site
    • Saarland
      • Saarbrücken, Saarland, 독일, 66111
        • Novartis Investigative Site
    • Saxony
      • Dresden, Saxony, 독일, 01307
        • Novartis Investigative Site
      • Leipzig, Saxony, 독일, 04103
        • Novartis Investigative Site
      • Schneeberg, Saxony, 독일, 08289
        • Novartis Investigative Site
    • Saxony-Anhalt
      • Halle, Saxony-Anhalt, 독일, 06118
        • Novartis Investigative Site
    • Thuringia
      • Jena, Thuringia, 독일, 07740
        • Novartis Investigative Site

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

18년 (성인, 고령자)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

모두

샘플링 방법

비확률 샘플

연구 인구

Patients being treated for nAMD or DME with brolucizumab were enrolled in the study upon signing an informed consent.

설명

Inclusion Criteria:

The unit of analysis was patient-eye, i.e. all criteria were applied to the study eye, unless otherwise specified. Patients were included in the study if they fulfilled the following requisites:

  1. Diagnosis of nAMD or visual impairment due to DME
  2. Male and Female nAMD and DME patients with ≥18 years of age at index
  3. Decision to treat with brolucizumab at baseline visit
  4. Signed written informed consent
  5. Patients for whom a therapy with brolucizumab was medically indicated
  6. Intraretinal and/or subretinal fluid affecting the central subfield of the study eye at Screening

Exclusion Criteria:

  1. Patients with any contraindication or who were not eligible for treatment with brolucizumab as according to the SmPC
  2. Patients treated for RVO or CNV other than nAMD
  3. Receipt of any anti-VEGF treatment other than brolucizumab in the study eye at index date
  4. Central subfield of the study eye affected by fibrosis or geographic atrophy or total area of fibrosis >50% of the total lesion (nAMD)
  5. Any active intraocular or periocular infection or active intraocular inflammation in either eye at index date
  6. Patients who have been on anti-VEGF treatment for longer than 3 years (before index date)
  7. Any medical or psychological condition in the treating physician's opinion which may have prevented the patient from the 24 months study participation
  8. Patients participating in parallel in an interventional clinical trial
  9. Patients participating in parallel in any other NIS generating primary data for an anti-VEGF drug
  10. Laser photocoagulation (focal/grid or panretinal) in the study eye during the 3-month period prior to baseline
  11. Prior use of intraocular or periocular corticosteroids in the study eye provided at least 4 months prior to baseline
  12. Pregnancy and breast-feeding

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 관찰 모델: COHORT
  • 시간 관점: PROSPECTIVE

코호트 및 개입

그룹/코호트
개입 / 치료
treatment naïve patients

Patients being the first time treated for nAMD or DME

There was no treatment allocation. Patients administered Brolucizumab by prescription that had started before inclusion of the patient into the study were enrolled.

pre-treated patients

Patients already being treated for nAMD or DME

There was no treatment allocation. Patients administered Brolucizumab by prescription that had started before inclusion of the patient into the study were enrolled.

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Percentage of patients' eyes that are absent of subretinal fluid (SRF) and intra-retinal fluid (IRF)
기간: Month 12

This outcome measure is part of the BLUE SKY AMD module. This primary study objective was addressed considering treatment naïve and pre-treated patient eyes, analyzed as two independent groups (naïve and switch).

Month 12
Mean change in visual acuity (VA) under clinic specific routine treatment schemes
기간: Baseline, month 12

This outcome measure is part of the BIRL module. This primary study objective was addressed considering treatment naïve patient eyes.

Index date (Baseline): defined as the date of the first anti-VEGF injection (brolucizumab) in patient eye.

Baseline, month 12
Morphological CNV-Changes under clinic specific routine treatment schemes
기간: Baseline, month 12

This outcome measure is part of the BIRL module. This primary study objective was addressed considering treatment naïve patient eyes.

Index date (Baseline): defined as the date of the first anti-VEGF injection (brolucizumab) in patient eye.

Baseline, month 12
Percent of patients maintained on q12w dosing after loading through Week 52
기간: After loading, month 12

This outcome measure is part of the BLUE SKY DME module. This primary study objective was addressed considering treatment naïve patient eyes included in the study.

After loading, month 12
Change in interval length from last interval before switch (baseline) to last interval at end of follow-up (12 months)
기간: Baseline, month 12

This outcome measure is part of the BLUE SKY DME module. This primary study objective was addressed considering pre-treated patient eyes. Index date (Baseline): defined as the date of the first anti-VEGF injection (brolucizumab) in patient eyes.

Baseline, month 12

2차 결과 측정

결과 측정
측정값 설명
기간
Characterize nAMD patients who initiated treatment with brolucizumab with the respect to baseline characteristics
기간: Baseline

nAMD patients. Detailed Outcome Measure as defined in the Statistical Analysis Plan

Baseline
Evaluate anatomical parameters during treatment with brolucizumab
기간: Up to month 24

nAMD patients. Detailed Outcome Measure as defined in the Statistical Analysis Plan.

Up to month 24
Evaluate VA change from baseline during treatment with brolucizumab
기간: Baseline, month 24

nAMD patients. Detailed Outcome Measure as defined in the Statistical Analysis Plan.

Baseline, month 24
Estimate number of anti-VEGF injections, visits and injection intervals
기간: Up to month 24

nAMD patients. Detailed Outcome Measure as defined in the Statistical Analysis Plan

Up to month 24
Estimate percentage of switchers during first 6 months and characterize switchers
기간: Baseline, month 6

nAMD patients. Detailed Outcome Measure as defined in the Statistical Analysis Plan

Baseline, month 6
Estimate discontinuation rate and time to discontinuation
기간: Month 1-12 and 13-24

nAMD patients. Detailed Outcome Measure as defined in the Statistical Analysis Plan

Month 1-12 and 13-24
Assess retreatment criteria
기간: Up to month 24

nAMD patients. Detailed Outcome Measure as defined in the Statistical Analysis Plan

Up to month 24
Estimate the number of OCT
기간: Month 1-12 and 13-24

nAMD patients. Detailed Outcome Measure as defined in the Statistical Analysis Plan

Month 1-12 and 13-24
Assess the safety of brolucizumab
기간: Up to month 24

nAMD patients. Detailed Outcome Measure as defined in the Statistical Analysis Plan

Up to month 24
Evaluate anatomical effectiveness
기간: Up to month 24

naive nAMD patients. Detailed Outcome Measure as defined in the Statistical Analysis Plan

Up to month 24
Evaluate treatment intervals
기간: Up to month 24

naive nAMD patients. Detailed Outcome Measure as defined in the Statistical Analysis Plan

Up to month 24
Describe implementation of treatment schemes into clinical practice
기간: Up to month 24

naive nAMD patients. Detailed Outcome Measure as defined in the Statistical Analysis Plan

Up to month 24
Evaluate morphological changes under brolucizumab treatment using multimodal imaging
기간: Up to month 24

naive nAMD patients. Detailed Outcome Measure as defined in the Statistical Analysis Plan

Up to month 24
Percentage of patient's eyes with absence of IRF and/or SRF at month 12 (naive and switch)
기간: Month 12

DME patients. Detailed Outcome Measure as defined in the Statistical Analysis Plan

Month 12
Evaluate anatomical parameters during treatment with brolucizumab
기간: Month 1-12 and 13-24

DME patients. Detailed Outcome Measure as defined in the Statistical Analysis Plan

Month 1-12 and 13-24
Characterize VA change from baseline during treatment with brolucizumab
기간: Month 1-12 and 13-24

DME patients. Detailed Outcome Measure as defined in the Statistical Analysis Plan

Month 1-12 and 13-24
Estimate discontinuation rate during first year of brolucizumab treatment
기간: Baseline, month 12

DME patients. Detailed Outcome Measure as defined in the Statistical Analysis Plan

Baseline, month 12
Estimate time to discontinuation (persistence)
기간: Up to month 24

DME patients. Detailed Outcome Measure as defined in the Statistical Analysis Plan

Up to month 24
Estimate the treatment burden
기간: Month 1-12 and 13-24

DME patients. Detailed Outcome Measure as defined in the Statistical Analysis Plan

Month 1-12 and 13-24
Estimate the number of OCT and the number of visits with/without OCT
기간: Month 1-12 and 13-24

DME patients. Detailed Outcome Measure as defined in the Statistical Analysis Plan.

Month 1-12 and 13-24
Assess safety of brolucizumab
기간: Up to month 24

DME patients. Detailed Outcome Measure as defined in the Statistical Analysis Plan.

Up to month 24

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

수사관

  • 연구 책임자: Novartis Pharmaceuticals, Novartis Pharmaceuticals

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (실제)

2020년 3월 18일

기본 완료 (실제)

2025년 11월 17일

연구 완료 (실제)

2025년 11월 17일

연구 등록 날짜

최초 제출

2020년 9월 4일

QC 기준을 충족하는 최초 제출

2020년 9월 4일

처음 게시됨 (실제)

2020년 9월 10일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 11월 20일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 11월 17일

마지막으로 확인됨

2026년 11월 1일

추가 정보

이 연구와 관련된 용어

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

아니요

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

아니

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .

구독하다